Your browser doesn't support javascript.
loading
Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin.
Barton, Elisabeth R; Pham, Jennifer; Brisson, Becky K; Park, SooHyun; Smith, Lucas R; Liu, Min; Tian, Zuozhen; Hammers, David W; Vassilakos, Georgios; Sweeney, H Lee.
Afiliación
  • Barton ER; Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Pham J; Applied Physiology and Kinesiology, College of Health and Human Performance, University of Florida, Gainesville, Florida.
  • Brisson BK; Department of Physiology, Perleman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Park S; Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Smith LR; Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Liu M; Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Tian Z; Department of Physiology, Perleman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Hammers DW; Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Vassilakos G; Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, Florida.
  • Sweeney HL; Applied Physiology and Kinesiology, College of Health and Human Performance, University of Florida, Gainesville, Florida.
Muscle Nerve ; 60(4): 464-473, 2019 10.
Article en En | MEDLINE | ID: mdl-31323135
ABSTRACT

INTRODUCTION:

Dysferlin loss-of-function mutations cause muscular dystrophy, accompanied by impaired membrane repair and muscle weakness. Growth promoting strategies including insulin-like growth factor 1 (IGF-1) could provide benefit but may cause strength loss or be ineffective. The objective of this study was to determine whether locally increased IGF-1 promotes functional muscle hypertrophy in dysferlin-null (Dysf-/- ) mice.

METHODS:

Muscle-specific transgenic expression and postnatal viral delivery of Igf1 were used in Dysf-/- and control mice. Increased IGF-1 levels were confirmed by enzyme-linked immunosorbent assay. Testing for skeletal muscle mass and function was performed in male and female mice.

RESULTS:

Muscle hypertrophy occurred in response to increased IGF-1 in mice with and without dysferlin. Male mice showed a more robust response compared with females. Increased IGF-1 did not cause loss of force per cross-sectional area in Dysf-/- muscles.

DISCUSSION:

We conclude that increased local IGF-1 promotes functional hypertrophy when dysferlin is absent and reestablishes IGF-1 as a potential therapeutic for dysferlinopathies.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Factor I del Crecimiento Similar a la Insulina / Músculo Esquelético / Disferlina Límite: Animals Idioma: En Revista: Muscle Nerve Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Factor I del Crecimiento Similar a la Insulina / Músculo Esquelético / Disferlina Límite: Animals Idioma: En Revista: Muscle Nerve Año: 2019 Tipo del documento: Article